Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus High-Dose Chemotherapy for Relapsed Non-Hodgkin's Lymphoma
NCT00143871Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2001
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Non-Hodgkin lymphoma (NHL), sponsored by University of Michigan Rogel Cancer Center. Started Apr 2001; status: completed.
02
Drugs
rituximab
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00143871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143871.